A Prospective, Multicenter Study of GE LightSpeed Volume Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain Patients Suspected of Coronary Artery Disease

GE Healthcare1 site in 1 country245 target enrollmentMay 2006

ConditionsCoronary Artery Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Coronary Artery Disease
Sponsor: GE Healthcare
Enrollment: 245
Locations: 1
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To compare computed tomography (CT) images (pictures) of the coronary arteries using the General Electric (GE) LightSpeed VCT scanner with x-ray coronary angiography in patients with typical or atypical chest pain suspected of coronary artery disease (CAD).

Registry

clinicaltrials.gov

Start Date

May 2006

End Date

January 31, 2007

Last Updated

7 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

GE Healthcare

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The subject has typical or atypical chest pain suspected of CAD and is referred for an elective coronary angiography.
•The subject must be scheduled to undergo a CATH procedure between 48 hours and 3 weeks post CCTA procedure.
•The subject must not undergo any cardiac interventional treatment between the 2 procedures.
•The subject must have sinus rhythm with stable heart rate of ≤65 beats per minute (bpm) or if heart rate was \>65 bpm, the subject must agree to the use of beta-blocker(s) prior to the CT scan procedure to achieve stable heart rate of ≤65 bpm.

Exclusion Criteria

•The subject had an established diagnosis of CAD by a) previous CATH, b) prior myocardial infarction confirmed by ECG, or c) prior revascularization (balloon angioplasty, stent placement, or CABG).
•The subject had a known allergy to iodinated contrast agent, including but not limited to hives, anaphylactoid or cardiovascular reactions, laryngeal edema and bronchospasm.
•The subject had impaired renal function with a serum creatinine level of 1.7 mg/dL (150 μmol/L) or above.
•The subject had atrial fibrillation/flutter or any irregular heart rhythm considered by the investigator to interfere with temporal acquisition of cardiac CT images.
•The subject had a resting heart rate of \>100 bpm and/or a resting systolic blood pressure of \<100mm Hg.
•The subject had an artificial heart valve(s).
•The subject has had prior pacemaker or internal defibrillator lead implantation.
•The subject's resting heart rate was \>65 bpm and beta-blocker therapy was contraindicated.
•The subject had a contraindication to verapamil when beta-blocker therapy could not be administered. The subject had a contraindication to nitroglycerin.
•The subject had evidence of ongoing or active clinical instability.